Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors

NCT02593708 is registered in ClinicalTrials.gov with Michelle Melisko as lead sponsor.

NCT NCT02593708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02593708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors
Lead sponsor
Michelle Melisko
Phase
Phase 1
Overall status
Terminated
Start date
November 3, 2015
Completion date
July 31, 2017
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor